In summary, although adverse drug–drug interaction may occur in combination therapy, our data suggest that combining conventional chemotherapeutic drugs with TMP195 may be a feasible therapeutic strategy to overcome cancer multidrug resistance associated with the overexpression of ABCB1 and/or ABCG2 and should be evaluated in future clinical studies. Here, ABCG2 is linked to cancer.